Why UnitedHealth Group (UNH) is a Top Momentum Stock for the Long-Term

Zacks rates UnitedHealth Group (UNH) #2 (Buy), with a VGM score of A and Momentum Style Score of B; shares rose 8.9% over the past four weeks. For fiscal 2026, 14 analysts raised earnings estimates in the past 60 days, lifting the consensus by $0.79 to $20.61 per share. The article also cites an average earnings surprise of +14%, but provides no new company guidance or reported results.

Analysis

The useful signal is the direction of estimate revisions, not the promotional “momentum” label: a broader upward revision cycle can support earnings expectations over the next quarter, but it does not establish that underlying medical-cost economics have improved. The cited score is designed around short-horizon signals; it is weak evidence for a long-term thesis. After a sharp recent run, incremental upside likely requires further estimate increases or reassuring guidance, while any reversal in revisions could amplify profit-taking.

For the next 1–3 months, focus on UNH’s reported medical-care cost trend, Medicare Advantage and Medicaid commentary, and whether guidance validates the higher EPS baseline. A higher-than-expected cost trend or weaker program economics could pressure margins and reset estimates; that would also weigh on managed-care peers such as Elevance Health, Humana, CVS Health, and Cigna, though exposure differs. Over 6–18 months, reimbursement policy and the ability to price or manage utilization matter more than a momentum score. The contrarian read: estimate upgrades may be catch-up rather than evidence of durable operating improvement, and the article supplies no valuation, earnings-quality, or cost-trend evidence. No compelling standalone trade follows from this source alone.

Key Decisions for Investors

• Do not chase the recent momentum solely on the Zacks ranking. Treat the estimate-revision trend as a watch signal; verify the actual revision distribution, valuation, and upcoming guidance before adding exposure.
• If already long, retain only while earnings revisions remain positive and management commentary supports the cost trend. Reassess on any guidance reduction, reversal in consensus estimates, or material adverse reimbursement update.
• Potential relative-value watch: compare UNH with Elevance Health, Humana, CVS Health, and Cigna after each company’s cost-trend and reimbursement disclosures; do not assume sector-wide effects are uniform.
• A bullish thesis is falsified by estimate cuts or an unfavorable medical-cost trend that undermines the current earnings baseline. The article gives no price levels or valuation data, so avoid setting a numeric target or defining a price-based stop from it.